
Vivek Subbiah/LinkedIn
Feb 4, 2025, 17:20
慈善信托产品规模逼近9亿 助力扶贫慈善信托优势多多
百度 中华文化、中国精神,亘古亘今、亦新亦旧,以整合性和包容力形成了一个“有着强大向心力的漩涡”。
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“FDA approves new non-opioid pain drug.
The FDA has approved Vertex’s suzetrigine (Journavx), an oral inhibitor of voltage-gated sodium channel 1.8 (NaV1.8), for the treatment of moderate to severe acute pain. The decision provides a much-needed new treatment option for acute pain management.”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 5, 2025, 16:29
Aug 5, 2025, 16:07
Aug 5, 2025, 16:04
Aug 5, 2025, 14:16
Aug 5, 2025, 13:23
Aug 5, 2025, 12:52